On the contrary, when the MSCs were co-injected with tumor cells in the immune competent syngeneic mice, the CCL2 KO MSCs indeed showed increased anti-tumor effects compared to wildtype MSCs (Figure 5d). Here, CCL2 is linked to neoplasm.